Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1

Background Neutralization of interferon (IFN)-γ abrogates the efficacy of anti-programmed death-ligand 1 (PD-(L)1) checkpoint inhibitors. Most epithelial cells do not constitutively express major histocompatibility complex (MHC) class II but can be induced to do so by IFN-γ. Inducible tumor-specific...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	David Cunningham, Paul Ross, Ruth Plummer, Joshua Savage, Gary Middleton, Mark Saunders, Daniel Palmer, Anne Thomas, Lucinda Billingham, Sally Clive, Vicky Coyle, John Bridgewater, Phillipe Taniere, Charlotte Gaskell
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BMJ Publishing Group 2025-12-01
Seri Bilgileri:	Journal for ImmunoTherapy of Cancer
Online Erişim:	https://jitc.bmj.com/content/13/12/e012749.full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!